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Oral feeding of renal tubular antigen abrogates interstitial nephritis
and renal failure in Brown Norway rats. We have examined whether oral
feeding of antigen can regulate the expression of autoimmune interstitial
nephritis induced by antigen-in-adjuvant (RTA'CFA) immunization of
Brown Norway rats. Male rats were divided into six experimental groups:
Group I, RTAJCFA immunization alone; Groups II, III, and IV were
pretreated with 1 mg (Group II), 5 mg (Group III), and 25 mg (Group IV)
of oral tubular antigen every other day for ten days, followed by RTAICFA
immunization; Group V was pretreated with a control antigen, followed by
RTAJCFA immunization; and Group VI was immunized with CFA alone.
Renal histology, inulin clearance, DTH responses to RTA, and IgG
antibody responses to RTA were monitored as endpoints of the study. Our
results demonstrated that Group III and IV animals had significantly less
severe renal injury, as assessed by inulin clearance and extent of renal
cortical involvement by mononuclear cells. Group II and IV animals had
suppressed DTH responses, and only Group IV animals had significantly
depressed antigen-specific IgG serum titers. Group III animals had
neither suppressed DTH responses or IgG titers. We conclude that oral
administration of tubular antigen can modulate the intensity of interstitial
nephritis produced by immunization, but that the regulatory mechanism is
not dependent (at all doses of fed antigen) on suppressed DTH reactivity
to RTA or suppressed antigen-specific IgG.
The term oral tolerance refers to the induction of systemic
hyporesponsiveness to an antigen following oral administration of
this antigen. Although the phenomenon was initially described in
the first half of this century [1, 2] there has been a recent
resurgence of interest in it because of its potential as a therapeutic
modality for autoimmune disease [3]. Oral feeding of proteins
that are target antigens of autoimmune T and B lymphocytes can
protect the host against subsequent immunization with those
antigens to induce disease. Amelioration of organ pathology by
this approach has been demonstrated in experimental allergic
encephalomyelitis [4, 5], myasthenia gravis [6], uveoretinitis [7],
and collagen arthritis [81. The mechanisms by which oral feeding
of protein antigens alter the nature of the subsequent immune
response to antigenic challenge are complex. Recent work has
demonstrated that the phenomenon of oral tolerance can be
attributed to active suppression by T lymphocytes or by clonal
anergy, depending the characteristics of the antigen and feeding
protocol [reviewed in 3].
Our laboratory has had a longstanding interest in developing
modalities of targeted immunosuppression in autoimmune renal
disease. One model system we utilize is that of anti-tubular
basement membrane (TBM) disease with interstitial nephritis.
This disease is induced in susceptible strains of guinea pigs, rats,
and mice by a single immunization of a renal tubular antigen
(RTA) emulsified in complete Freund's adjuvant (CFA) [9—li].
The resultant humoral and cell-mediated immune response to
RTA results in deposition of specific IgG along the tubular
basement membrane and mononuclear cell infiltration of renal
interstitium. This mononuclear cell infiltrate includes both CD4
and CD8 T cells, as well as macrophages, natural killer cells, and
B cells [121. The relative importance of these various immune cell
subsets, as well as antigen-specific lgG, in mediating renal injury
varies among species [13]. For example, the passive transfer of
anti-TBM antibodies can induce disease in guinea pigs [14, 15], to
a lesser degree in rats [16], and not at all in mice. Susceptibility to
disease depends, at the minimum, on expression of discrete MHC
genes [11], expression of antigen in the kidney [17], and the
development of a susceptible T cell phenotype following immu-
nization [18—20]. The animals develop progressive renal failure.
Previous work in this model has documented that this nephrito-
genie immune response can be modulated by immunosuppressive
drugs [21, 22] dietary manipulation [231, PGEI [24], and through
the induction of regulatory T cells [9, 25—28]. Regulatory T cells
can be induced through the presentation of antigen in a tolero-
genie manner, that is, emulsified with IFA rather than CFA [9], or
coupled to the surface of syngeneic splenocytes and injected
intravenously [27]. In the studies reported here, we examined
whether oral administration of renal tubular antigen can alter the
development of interstitial nephritis. We find that oral feeding of
RTA can abrogate the severity of the induced interstitial ncphri-
tis, and that this effect is demonstrable at doses of fed antigen at
which anti-1BM lgG titers and DTH reactivity arc not altered.
METHODS
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Animals
Male Brown Norway rats weighing 200 to 25(1 g were purchased
from Charles River Laboratories (Boston, MA, USA) and housed
in the animal facility at the San Diego Veterans Affairs Medical
Center. All care of animals was performed under guidelines
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approved by the American Association for the Accreditation of
Laboratory Animal Care.
Immunization of animals
Rabbit renal tubular basement membranes were isolated by a
differential sieving technique, sonicated, lyophilized, and stored at
—20°C [9]. Lyophilized renal tubular antigen was emulsified in
complete Freund's adjuvant (RTAJCFA). Antigen concentrations
for both RTA and PPD (M.Th. H37Ra; Difco Laboratories,
Detroit, MI, USA) were 4 mg/mI. After the induction of anesthe-
sia with Brevital (7 mg/100 g body wt., i.p.; Eli Lilly & Co.,
Indianapolis, IN, USA), animals were immunized subcutaneously
into four sites in the axillary and groin regions with a total of 0.75
ml of RTA/CFA. One group of animals received 0.75 ml of CFA
alone (4 mg/mI PPD) as a control for the immunization proce-
dure. In these studies no animal received footpad immunization
with RTA/CFA or CFA.
Feeding protocol
For the three groups of rats that received RTA or control
antigens (ovalbumin or hemoglobin; Sigma Chemical Co., St.
Louis, MO, USA) in the food, the antigen was mixed thoroughly
in powdered rat chow prior to feeding. Animals were housed in
individual cages and fed 14 g of standard rat chow daily for a
period of ten days. (This quantity of powdered rat chow was
selected because it was completely consumed daily). Antigen in
designated amounts was mixed with the food on alternate days.
The two groups of rats that did not receive RTA or control
antigens in the food were also housed individually and given 14 g
of food daily for ten days. After the 10-day regimen of food intake,
all rats were fed normal rat chow and water ad libitum and housed
at three rats per cage.
Experimental groups
Animals were divided into six groups. Group I (N = 6) was
immunized with RTA/CFA two days following completion of
feeding regimen. This group served as a positive control for
disease severity. Group II (N = 4) was fed with I mg of RTA in
powdered rat chow on alternate days as described above (total of
5 mg fed antigen). Group III (N = 8) was fed with 5 mg of RTA
in powdered rat chow on alternate days (total of 25 mg fed
antigen). Group IV (N = 4) was fed with 25 mg of RTA in
powdered rat chow on alternate days (total of 125 mg fed
antigen). Group V (N = 5) was fed with either ovalbumin or
hemoglobin as control antigens. All animals in groups II to V were
immunized with RTA/CFA two days following completion of the
feeding regimen. Group VI (N = 4) was immunized with CFA two
days following completion of feeding regimen. This group was
used as a control for normal renal function. Previous work from
our laboratory has shown that at one and three weeks following
CFA immunization, glomerular filtration rate is indistinguishable
from that of animals never immunized (C. Kelly and F. Gabbai,
unpublished data).
Delayed-type hypersensitivity testing
At 13 to 15 days following subcutaneous immunization with
RTA/CFA, all rats received a challenge dose of antigen, consisting
of 75 jd of I mg/ml collagenase solubilized RTA in PBS in one
hind footpad. The other hind footpad was injected with PBS.
Footpad thickness was measured before and 24 hours after
challenge by an independent observer blinded to the identity of
the experimental groups, using a spring-loaded engineer's micro-
meter. The change in footpad thickness was recorded for each
animal and the result expressed as the mean for each experimen-
tal group SEM.
Assessment of renal function
At 17 to 18 days following initial immunization, all rats under-
went an inulin clearance as a measure of glomerular filtration
rate, using established techniques. Briefly, following anesthesia
with mactin (10 mgIlOO g body wt, i.p.; BYK, Konstanz, Germa-
ny), animals were tracheally intubated, and catheters were in-
serted in the jugular vein, femoral artery, and urinary bladder.
The femoral artery catheter was used for periodic blood sampling
and monitoring mean arterial pressure with a transducer (model
P23DB; Statham Instruments, Gould Divsion, Hato Rey, Puerto
Rico) and recorded on a chart recorder. All rats received an
infusion of NaC1-NaHCO3 throughout the experiment containing
(3H) inulin at a rate of 2.2 ml/hr. After 60 minutes of equilibra-
tion, plasma and urine samples were collected for three consecu-
tive 20-minute periods from femoral artery and urinary bladder,
respectively. Aliquots of plasma and urine samples were counted
in a scintillation counter (Packard Instruments, Downer's Grove,
IL, USA). Glomerular filtration rate was calculated from the
radioactivity counts of the plasma and urine aliquots and the
volume of urine collected per 20 minute period.
ELISA for anti-RTA antibodies
ELISA microtiter plates were coated overnight at 4°C with
collagenase solubilized RTA at 40 jig/mI. Following washing with
dH2O, the plates were blocked for two to three hours at room
temperature with PBS containing 4% BSA, 0.05% Tween 20.
Following extensive washing with Tris-buffered saline with 0.05%
Tween 20, pH 7.6, multiple dilutions of test sera from individual
animals were placed in wells, and incubated at 37°C for 2.5 hours.
Following extensive washing, the appropriate secondary reagent
[goat anti-rat IgG (H+L), goat anti-rat IgGI or goat anti-rat
IgG2a diluted in PBS with 4% BSA, 0.05% Tween 20, all alkaline
phosphatase conjugated] was added and incubated for 2.5 hours at
37°C. Following washing, the plates were developed with substrate
in carbonate buffer, pH 9.6, for the appropriate time period (45
mm for total IgG, 5 hr for IgG subtype ELISA). The O.D. at 405
nm was measured in a microplate reader. The best linear curve fit
for each group (as determined by the linear least-squares regres-
sion method) was calculated, and the serum titer for each group
was calculated as the serum dilution at which the test sera O.D.
405 nm was equal to the O.D. 405 for CFA serum.
Assessment of histologic renal disease
Animals were sacrificed following the clearance measurements
(at day 18 following immunization). The left kidney of each rat
was harvested and immersion fixed in 10% buffered formalin. The
extent of interstitial involvement was determined by a single
observer from 4 mm, paraffin-embedded kidney sections stained
with hematoxylin and eosin. The specimens were coded to prevent
observer bias, and graded at a single session by an observer who
additionally was unaware of the results of the clearance measure-
ments. Cellular infiltration and tubular damage leading to cortical
interstitial destruction was graded on a scale of 0 to 4: 0 = no
lesions; 1.0 or greater = 10 to 25% cortical involvement by
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Fig. 1. Oral feeding of RTA can diminish the severity of interstitial
nephritis. Experimental groups (designated by Roman numerals on the
horizontal axis) of Brown Norway rats were fed with varying total doses of
RTA prior to immunization to produce interstitial nephritis. The feeding
protocols are outlined in the Methods section. Experimental group
designations are: I, RTAICFA immunized with no oral antigen fed; II, fed
with I mg RTA every other day for ten days prior to immunization with
RTA/CFA; HI, fed with 5 mg RTA every other day for ten days prior to
immunization with RTAJCFA; IV, fed with 25 mg RTA every other day
for ten days prior to immunization with RTAICFA; V, fed with control Ag
prior to immunization with RTAJCFA; VI, no antigen feeding, immunized
with CFA alone. Group VI animals have no detectable disease. p < 0.05
compared with Group I.
inflammatory cells; 2.0 or greater 25 to 50% cortical involve-
ment by inflammatory cells; 3.0 or greater = 50 to 75% cortical
involvement by inflammatory cells; 4.0 = 75% or greater cortical
involvement by inflammatory cells. 4.0 was the maximum score
assigned.
Statistical analysis
Results are presented as mean SEM. ANOVA with post hoc
tests was used for comparison among groups. The level of
statistical significance was defined as a value of P < 0.05.
RESULTS
Oral feeding of tubular antigen blocks the development of
interstitial nephritis following RTAICFA immunization
Figure 1 shows the effect of oral feeding of RTA on the
histologic severity of the interstitial injury. The grading scale for
interstitial injury extends from 0 to 4 and represents the extent of
cortical involvement by the mononuclear cell infiltrate. The
positive control animals (Group I), those fed Ix oral antigen
(Group II), and those fed the control Ags (Group V), all had
mean histologic scores in the 2.75 to 3.0 range, signifying approx-
imately 50% cortical involvement. Animals fed either 5x (Group
III) or 25x (Group IV) oral antigen had histologic scores of
approximately 1, signifying 10% cortical involvement. These latter
differences were statistically significant. CFA immunized animals
(Group VI) do not have detectable disease.
Oral feeding of tubular antigen leads to preserved GFR
following RTAJCFA immunization
To have a precise quantitative endpoint (GFR) by which to
compare experimental groups, we performed inulin clearances on
all animals at 17 to 18 days following RTAICFA immunization.
These data are shown in Figure 2. The mean inulin clearance for
the CFA immunized rats (Group VI) was 1.9 mi/mm, establishing
the control values for male BN rats of this weight. RTA/CFA
immunized animals (Group I) had a markedly diminished GFR at
approximately 0.5 mI/mm. Oral antigen feeding had a dose
dependent effect on GFR. Although the mean GFR for Group II
was not significantly different than Group I, the mean GFR for
Groups III and IV, the 5x and 25 X oral antigen groups was
significantly different from Group I and, in fact, not significantly
different than that of the normal controls (Group VI). Control
antigen feeding (Group V) did not significantly improve GFR.
Close correlation between the GFR and histology score in
Groups I-V
Figure 3 depicts a plot of mean inulin clearance versus mean
histologic score for each experimental group immunized with
RTA/CFA. There is a close inverse correlation between GFR and
extent of cortical interstitial inflammation (linear correlation
coefficient, r = 0.972).
Antigen-feeding resulted in a dose-dependent inhibition of DTH
responses to RTA
The DTH response to RTA has correlated well in previous
studies with the presence of nephritogenic lymphocytes and active
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Fig. 2. Oral feeding of antigen leads to improved renal function. Inulin
clearances were performed on the same experimental groups outlined in
the Figure 1 legend and the Methods section. *P < 0.05 compared with
Group I.
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Fig. 3. A close correlation exists between inulin clearance and histologic
score in the experimental groups. The mean inulin clearances from each
experimental group (except Group VI, where the histologic score is zero)
were plotted on the horizontal axis versus the mean histologic scores on
the vertical axis. The best linear curve fit for these data (as determined by
the linear least-squares regression method) was determined using CA-
Cricket Graph III" software (Computer Associates, International). The
equation for this line is y = —1.70x + 4.21, r = 0.972.
interstitial nephritis [9, 20, 29]. Figure 4 illustrates the DTH
responses to collagenase solubilized RTA at 14 days after immu-
nization in all six groups of animals. The groups fed with repeated
doses of 1 mg (Group II) or 25 mg (Group IV) of RTA
demonstrated marked suppression of DTH responses to RTA
compared to Group I animals. Group Ill, fed with repeated doses
of 5 mg of RTA, had a DTH response not significantly different
than Group I. The group fed with irrelevant antigens also
displayed no suppression of DTH to RTA, as expected. The
change in footpad thickness in response to PBS injection alone
ranged from a mean of 1.0 to 5.9 in the different groups. (The data
from the PBS injected footpad are not depicted on Fig. 4 for the
sake of clarity.) These experiments demonstrate that oral feeding
of this antigen preparation is capable of modulating one marker
of the cell-mediated immune response to RTA.
Antigen feeding does not affect the anti-TBM antibody response
We also examined the titers of aTBM IgG antibodies in the
various experimental groups (Fig. 5). The mean O.D. readings
versus serum dilution for the different experimental groups are
depicted in Figure SA. The titers derived from these readings for
each experimental group are compared in Figure SB. Although
the mean O.D. readings at some serum dilutions were depressed
for both Groups II and V, only group IV had a significantly
depressed total lgG aTBM Ab serum titer. Even with this slightly
depressed log10 titer, the kidneys of Group IV animals still had 4
positive linear TBM staining for IgG by direct immunofluores-
cence and were indistinguishable from the Group I animals by
intensity of immunofluorescence (data not shown). Therefore, the
II Ill I\/ \'I
Fig. 4. "Low" and "high" dose oral antigen feeding inhibit DTH reactiv-
ity to RTA. DTH testing for reactivity to RTA was performed on all
experimental groups several days prior to performance of the inulin
clearances. Footpads were read on unanaesthetized animals using an
engineer's micrometer in cage-blind fashion. Results are depicted as the
change in footpad thickness measurement from that prior to RTA
injection to that measured 24 hours following RTA challenge. p < 0.01
compared with group I.
biologic significance of this slightly depressed anti-TBM IgG titer
is uncertain.
Since other groups have reported a preferential inhibition of
ThI CD4 cells over Th2 responses at low doses of oral antigen,
we additionally examined the titers of the IgGi and IgG2a
subtypes in the csTBM antibody responses in these animals. IgGI
responses typically correlate with a Th2 response, and IgG2a
responses correlate with a Thi response. We found no significant
differences in the ratio of these subtypes compared with control
animals (data not shown).
DISCUSSION
Our studies clearly demonstrate that oral feeding of RTA to
Brown Norway rats prior to immunization with RTAJCFA can
block the subsequent development of interstitial nephritis and
renal insufficiency. The effect of antigen feeding is dose depen-
dent. Although certain doses of fed antigen had significant
suppressive effects on DTH responses to RTA, the DTH effect did
not correlate well with improvement in histologic disease or GFR.
When one compares the two experimental groups in which there
was improvement in GFR and histologic disease (Groups III and
IV), it is evident that neither inhibition of DTH reactivity to the
immunogen, nor inhibition of the IgG antibody titer is required to
ameliorate this disease process within the time frame of our
studies.
The term "oral tolerance" is used to describe the alterations in
immune responsiveness seen following feeding of various anti-
gens. While this widely used phrase evokes the protective nature
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Fig. 5. Anti-RTA IgC titers are suppressed only in Group IV animals. (.4)
The mean O.D. readings flr each experimental group at the indicated
serum dilutions. Only positive error defiections (1 su) are shown. Icons for
Groups Ito VI are as follows: () Group I; () Group U; (0) Group III;
(0) Group IV; () Group V; (+) Group VI. The best linear curve fit for
each group (as determined by the linear leastsquares regression method)
was calculated, and the serum titer taken as the serum dilution at which
the test sera 0D405 nm was equal to the 00405 for CFA serum. (B)
Values for the linear curve fit. Only the Group TV data are significantly
different. Where error bars are not depicted, they were insignificant in
size. P 0.05.
of the subsequent immune response to challenge immunizations
with the same antigen (in the ease of autoimmune disease), it is
not, strictly speaking, tolerance, nor does this protective effect
require oral feeding. Similarly protective effects have been shown
with aerosolized antigen [301 and antigen applied to the nasal
mucosa [311. In these instances, the antigen processing by either
bronchial or nasal mucosa associated lymphoid tissue presumably
induces the same type of protective response as does the gut-
associated lymphoid tissue.
Our study is the first to demonstrate abrogation of renal
inflammation and preservation of renal function by the oral
administration of a renal target antigen. Two previous studies in
models of immune-mediated renal disease have supported the
notion that presentation of antigen via the gut mucosa can
modulate the expression of renal disease. Oral feeding of HSA
can decrease the incidence of immune complex disease in the
kidney despite continued presence of high levels of circulating
immune complexes [32]. The decreased incidence of immune
complex disease was attributed to a possible change in the affinity
of the immune complexes. In a model of IgA nephropathy
induced by oral feeding of bovine gamma globulin, the concomi-
tant administration of cyclophosphamide or estradiol increased
Ag-specific IgG responses, glomerular IgG immune deposits and
the development of hematuria. Both drugs can interfere with the
development of oral tolerance, thereby supporting a paradigm
whereby defective oral tolerance facilitates the development of
this form of glomerulonephritis [33].
The mechanisms underlying how oral feeding of antigen abro-
gates autoimmune responses have been evaluated in several other
models of organ-specific autoimmune disease. Experimental al-
lergic encephalomyelitis (EAE) has been the most extensively
studied model system [3]. Studies have been conducted in both the
rat and mouse models of this disease. In rat EAE, clinical and
histologic manifestations of disease can be suppressed by low
doses of fed myelin basic protein [4, 51. In this model, animals fed
with MBP have a CD8 T cell population demonstrable in their
spleen and mesenterie lymph nodes that can adoptively transfer
protection against EAE [34, 35]. The antigenic epitopes of MBP
recognized by these regulatory T cells are distinct from those
recognized by encephalitogenic T cells [36]. In the murine model
of EAE, antigen feeding induces Th2-like CD4 regulatory T cells
that produce TGF-f3 and IL-4 and functionally suppress EAE
induced with either MBP or proteolipid protein [37]. These
studies suggest that inactivation, rather than deletion, of effector
T cells is a generic operative mechanism in oral tolerance. This
notion is further supported by recent studies utilizing a system of
V ovalbumin specific TCR transgenic lymphocytes transplanted into
BALB/c recipients which were subsequently fed and challenged
with ovalbumin [38]. in this system, the proliferative norirespon-
siveness seen in fed animals could be normalized for the number
of antigen specific cells. This calculation demonstrated a marked
reduction in proliferation per lymphocyte expressing the ovalbu-
mm specific TCR in antigen fed animals, supporting a tolerance
mechanism of anergy (inactivation) rather than deletion [38]. It is
important to point out this kind of proliferative nonresponsive-
ness could be secondary to the induction of Th2-like cytokines in
the TCR transgenic T cells.
Previous experimental work in both the rat and murinc models
of <XTBM disease has consistently demonstrated a close correla-
tion between the DTH response to tubular Ag and the presence of
cortical mononuclear cell infiltrates. Immunosuppressive modali-
ties, such as drugs [21, 22] or Ag-specific regulatory T cells 19, 18,
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24, 25, 29], which abrogate disease have consistently also abro-
gated Ag-specific DTH responses. The relationship between
DTH-reactivity and nephritogenicity is more than a correlative
presumption of pathogenicity. T cells purified from diseased
kidneys mediate DTH to the tubular Ag, and renal-eluted DTH
reactive cells can infiltrate the renal cortex following adoptive
subcapsular transfer into naive hosts [20, 39]. Moreover, tubular
Ag-reactive T cell clones that can mediate DTH are also nephri.
togenic following adoptive transfer [40, 41]. These findings have
strongly supported the notion that DTH-reactive T cells are
important effector cells in experimental interstitial nephritis. The
uncoupling of DTH reactivity to tubular Ag and protection from
interstitial nephritis (as displayed by Group III in this study) was
surprising to us. It is possible that DTH-reactivity to the Ag is an
epiphenomenon and unrelated to the immunopathogenesis of
disease. For the reasons outlined above, we do not favor this
interpretation. Another possibility is that the DTH-reactive cell is
the critical effector cell, but that antigen feeding protocols result
in impaired homing to the kidney, perhaps through cytokine
induced alterations in integrins or selectin ligands. An alternative
interpretation is that the oral feeding regimen results in the
inactivation of a different T cell population, not DTH reactive,
which is required for interstitial injury. This could be a CD8 CTL
population, or a functionally distinct CD4 subpopulation. The
last two scenarios described above (impaired homing vs. a non-
DTH-reactive effector cell) are not mutually exclusive. The mech-
anism underlying the preserved DTH response in group III has
not yet been elucidated. In preliminary studies, we have found
that the mechanisms underlying suppression of DTH in Group II
and IV animals are different. This finding suggests that Group III
animals received an antigen dose orally which did not activate
either suppressive mechanism. We were not surprised by the
discordance between Ag-specific IgG titers, histologic renal dis-
ease, and functional deterioration. Previous studies have demon-
strated marked suppression of renal disease in this model, without
alterations in circulating Ag-specific IgG or kidney bound IgG [9].
There was a striking correlation between histologic scores and
GFR in our studies. We performed both measurements as they
provided a complementary analysis. The inclusion of the inulin
clearance contributed a "hard" endpoint to the analysis. Given the
well-recognized inverse correlation between degree of interstitial
damage and glomerular filtration rate in human renal disease
[42-44], it is not surprising that an experimental model of
interstitial inflammation should result in impaired GFR. The
close correlation between function and histology in the current
study is reassuring support for the use of the latter as an important
endpoint. Despite this strong correlation, we still believe that both
measurements are important. In the context of immunomodula-
tion, it is quite possible that an immunosuppressive modality that
altered the types of cytokines expressed by Ag-reactive cells might
not change the degree of mononuclear cell infiltration but would
improve renal function. In contrast, other immunosuppressive
agents that result in the virtual elimination of Ag-reactive lym-
phocytes from the renal cortex might depress GFR, through either
functional or toxic mechanisms.
The finding that oral administration of antigen can prime T
cells which produce cytokines with immunosuppressive properties
(that is, IL-4, IL-b, and TGF-13) suggested that the final mediator
of immunosuppression was Ag-nonspecific. TGF-p in particular
has been implicated as a mediator [36, 37]. A potential role for
TGF-p as an immunosuppressive cytokine would be fully consis-
tent with our previous observations regarding TGF-/3 in this
model system [45—47]. This finding has important practical impli-
cations, as it implies that it is not necessary to purify a target
antigen to homogeneity, or even identify a target antigen, in order
to induce this protective effect. Our own studies confirm this, as
we used a renal tubular antigen preparation which consists of 15
to 20 distinct protein bands by SDS-PAGE [48]. Previous studies
have demonstrated that rodents mount a significant immune
response to a single component of RTA, the 3M—I protein,
following immunization with RTAJCFA [48]. While the remaining
proteins in the RTA preparation are innocuous from the stand-
point of generating a nephritogenic immune response, it is
possible that they generate protective responses when presented
via the gut mucosa, and thereby contribute to the induced
tolerance. Another implication of immunosuppression by Ag-
nonspecific cytokines is that feeding with a single antigen ex-
pressed in physical proximity to the target antigen could abrogate
immune responses directed to the target antigen, by local produc-
tion of immunosuppressive cytokines [491. This raises the possi-
bility that feeding an "irrelevant" antigen, but one expressed in
the tubules or interstitium, may stimulate a host protective
response.
Our studies demonstrated equivalent protection by the antigen
doses in Groups III and IV. These studies have not established the
minimum total dose or timing necessary to induce oral tolerance.
We believe that the dose administered to Group II, 5 mg total, is
on the border of what is effective. The large standard error
displayed in this group in both Figures 1 and 2 is the result of
some animals displaying protection and other animals displaying
none. The correlation between histology and inulin clearance
within Group II is strong, that is, those animals with minimal
histologic abnormalities have the higher inulin clearances. We
have not seen any protection with doses of this RTA antigen
preparation below this dose (data not shown). It is also possible
that the gastrointestinal absorption of the antigen is variable. The
quantity of antigen used may be minimized by coupling to cholera
toxin [50]. An important second-order study will be to determine
the efficacy of oral Ag feeding after induction of disease.
Preliminary data from several clinical trials suggested that Ag
feeding may have beneficial effects clinically in autoimmune
disease, with minimal toxicity or side effects [51, 521, although
more recent observations in non-human primates partially temper
this early enthusiasm for the therapeutic potential of immune
deviation to the Th2 phenotype [53]. The appeal of this as a
potential therapy for human immune-mediated renal disease is
that the knowledge of a precise target antigen is probably not
required. It is additionally possible that in complex lesions, such as
the interstitial inflammatory disease accompanying heavy protein-
uric states, inhibition of an antigen-specific secondary immune
response targeted to the interstitium might block progression of
disease. Further work on oral tolerance in experimental renal
disease may provide a foundation for a novel approach to
treatment of immune-mediated renal disease.
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